AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
3don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Stocktwits on MSN4d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $ ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Shares of AbbVie Inc. ABBV tumbled 12.57% to $174.43 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to 6,001.35 ...
Pharmaceutical stocks declined as President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department ...
I last wrote on AbbVie Inc. (NYSE:ABBV) back in September 2024 and on Pfizer Inc. (NYSE:PFE) back in August 2024. These articles are titled “AbbVie: Dividend Discount Model Suggests Large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback